Amgen Inc. has announced the rapid acceleration of its clinical trial program for obesity, marking it as one of the largest in the company's 45-year history. The investigational medicine, maridebart cafraglutide, also known as MariTide, is at the center of the Phase 3 MARITIME program. This program aims to evaluate the safety and efficacy of MariTide for the treatment of obesity and obesity-related conditions. The MARITIME program includes MARITIME-1, a study focused on individuals with overweight or obesity, and MARITIME-2, which targets those living with type 2 diabetes and overweight or obesity. The results of these trials have not yet been presented. Further updates and information about the Phase 3 clinical program can be accessed through the MARITIME website.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。